Literature DB >> 17523132

Inhibition of endogenous MHC class II-restricted antigen presentation by tacrolimus (FK506) via FKBP51.

Akihito Imai1, Hiroeki Sahara, Yasuaki Tamura, Kowichi Jimbow, Tamotsu Saito, Kyori Ezoe, Takatoshi Yotsuyanagi, Noriyuki Sato.   

Abstract

The effect of tacrolimus (FK506) on down-regulation of IL-2 production by T cells is considered to be mainly responsible for its strong suppression of immunological events. In this study, we show that FK506 also has an affect on antigen presentation by antigen-presenting cells in vitro. FK506 was able to inhibit the presentation of endogenous MHC class II-restricted minor histocompatibility antigens in primary dendritic cells (DC) in vitro, but cyclosporine A (CsA) and rapamycin (RAP) were not. RNA interference (RNAi)-mediated reduction of endogenous FK506-binding protein (FKBP)51 expression resulted in a marked decrease in antigen presentation, suggesting that FKBP51 plays a role in endogenous MHC class II-restricted antigen presentation. Since our model used naturally expressed cytosolic antigens in primary DC, these effects might have been due to novel properties of the immunosuppressive drugs and may allow us to elucidate a new paradigm for the immunosuppressive mechanism of FK506.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523132     DOI: 10.1002/eji.200636392

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  FKBP51 and FKBP52 in signaling and disease.

Authors:  Cheryl L Storer; Chad A Dickey; Mario D Galigniana; Theo Rein; Marc B Cox
Journal:  Trends Endocrinol Metab       Date:  2011-08-31       Impact factor: 12.015

Review 2.  Dendritic Cells and Macrophages: Sentinels in the Kidney.

Authors:  Christina K Weisheit; Daniel R Engel; Christian Kurts
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 8.237

Review 3.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

4.  Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection.

Authors:  Jonah B Sacha; Juan P Giraldo-Vela; Matthew B Buechler; Mauricio A Martins; Nicholas J Maness; Chungwon Chung; Lyle T Wallace; Enrique J León; Thomas C Friedrich; Nancy A Wilson; Atsunobu Hiraoka; David I Watkins
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-28       Impact factor: 11.205

5.  Treg cell resistance to apoptosis in DNA vaccination for experimental autoimmune encephalomyelitis treatment.

Authors:  Youmin Kang; Yuhan Sun; Jingyao Zhang; Wenjuan Gao; Jingjing Kang; Yongqiang Wang; Bin Wang; Guoliang Xia
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

6.  Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B.

Authors:  Kengo Morohashi; Hiroeki Sahara; Koichi Watashi; Kazuki Iwabata; Takashi Sunoki; Kouji Kuramochi; Kaori Takakusagi; Hiroki Miyashita; Noriyuki Sato; Atsushi Tanabe; Kunitada Shimotohno; Susumu Kobayashi; Kengo Sakaguchi; Fumio Sugawara
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

7.  Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin.

Authors:  Julien Lion; Maren Burbach; Amy Cross; Karine Poussin; Cécile Taflin; Srini Kaveri; Alain Haziot; Denis Glotz; Nuala Mooney
Journal:  Front Immunol       Date:  2017-12-14       Impact factor: 7.561

8.  Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients.

Authors:  Lena Peter; Désirée Jacqueline Wendering; Stephan Schlickeiser; Henrike Hoffmann; Rebecca Noster; Dimitrios Laurin Wagner; Ghazaleh Zarrinrad; Sandra Münch; Samira Picht; Sarah Schulenberg; Hanieh Moradian; Mir-Farzin Mashreghi; Oliver Klein; Manfred Gossen; Toralf Roch; Nina Babel; Petra Reinke; Hans-Dieter Volk; Leila Amini; Michael Schmueck-Henneresse
Journal:  Mol Ther Methods Clin Dev       Date:  2022-02-26       Impact factor: 6.698

9.  Cell therapy using tolerogenic dendritic cells in transplantation.

Authors:  Aurélie Moreau; Emilie Varey; Laurence Bouchet-Delbos; Maria-Cristina Cuturi
Journal:  Transplant Res       Date:  2012-09-28

Review 10.  Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation.

Authors:  Giuseppe Vassalli
Journal:  J Transplant       Date:  2013-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.